The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes

Seminars in Neurology

Volumn 34, Issue 2, 2014, Pages 202-209

  Holtbernd, Florian ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

atypical parkinsonism; differential diagnosis; neuroimaging; Parkinson disease

Indexed keywords

IRON; TRACER;

ARTICLE; BASAL GANGLION; CARDIAC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DOPAMINERGIC SYSTEM; FUNCTIONAL NEUROIMAGING; HUMAN; MORPHOMETRICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; VOLUMETRY; BRAIN; DIAGNOSTIC IMAGING; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

BRAIN; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; NEUROIMAGING; PARKINSONIAN DISORDERS;

EID: 84903316737     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1381733     Document Type: Article

References (89)

1. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry: 1992; 55 3 181 184
2. Litvan I., Booth V., Wenning G. K., et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm: 1998; 105 2-3 217 227
3. Respondek G., Roeber S., Kretzschmar H., et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord: 2013; 28 4 504 509
4. Postuma R. B., Aarsland D., Barone P., et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord: 2012; 27 5 617 626
5. Kalra S., Grosset D. G., Benamer H. T. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord: 2010; 25 2 149 156
6. Massey L. A., Micallef C., Paviour D. C., et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord: 2012; 27 14 1754 1762
7. Wenning G. K., Colosimo C., Geser F., Poewe W. Multiple system atrophy. Lancet Neurol: 2004; 3 2 93 103
8. Schwarz J., Weis S., Kraft E., et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry: 1996; 60 1 98 101
9. Tolosa E., Wenning G., Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol: 2006; 5 1 75 86
10. Quattrone A., Nicoletti G., Messina D., et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology: 2008; 246 1 214 221
11. Paviour D. C., Price S. L., Jahanshahi M., Lees A. J., Fox N. C. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord: 2006; 21 7 989 996
12. Messina D., Cerasa A., Condino F., et al. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord: 2011; 17 3 172 176
13. Kashihara K., Shinya T., Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosc: 2011; 18 1093 1096
14. Ziegler D. A., Wonderlick J. S., Ashourian P., et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol: 2013; 70 2 241 247
15. Jesse S., Kassubek J., Müller H. P., Ludolph A. C., Unrath A. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. BMC Neurol: 2012; 12 163
16. Gröschel K., Hauser T. K., Luft A., et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage: 2004; 21 2 714 724
17. Josephs K. A., Tang-Wai D. F., Edland S. D., et al. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol: 2004; 61 12 1881 1884
18. Ashburner J., Friston K. J. Voxel-based morphometry-the methods. Neuroimage: 2000; 11 6 Pt 1 805 821
19. Pereira J. B., Ibarretxe-Bilbao N., Marti M. J., et al. Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp: 2012; 33 11 2521 2534
20. Beyer M. K., Janvin C. C., Larsen J. P., Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry: 2007; 78 3 254 259
21. Biundo R., Formento-Dojot P., Facchini S., et al. Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci: 2011; 310 1-2 64 69
22. Ramírez-Ruiz B., Martí M. J., Tolosa E., et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol: 2005; 252 11 1345 1352
23. Yang J., Shao N., Li J., Shang H. Voxelwise meta-analysis of white matter abnormalities in progressive supranuclear palsy. Neurol Sci: 2014; 35 1 7 14
24. Shi H. C., Zhong J. G., Pan P. L., et al. Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies. Neurol Sci: 2013; 34 7 1049 1055
25. Hauser T. K., Luft A., Skalej M., et al. Visualization and quantification of disease progression in multiple system atrophy. Mov Disord: 2006; 21 10 1674 1681
26. Minnerop M., Specht K., Ruhlmann J., et al. Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage: 2007; 36 4 1086 1095
27. Shigemoto Y., Matsuda H., Kamiya K., et al. In vivo evaluation of gray and white matter volume loss in the parkinsonian variant of multiple system atrophy using SPM8 plus DARTEL for VBM. Neuroimage Clin: 2013; 2 491 496
28. Brenneis C., Boesch S. M., Egger K. E., et al. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. Mov Disord: 2006; 21 2 159 165
29. Brenneis C., Seppi K., Schocke M. F., et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord: 2003; 18 10 1132 1138
30. Boxer A. L., Geschwind M. D., Belfor N., et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol: 2006; 63 1 81 86
31. Josephs K. A., Whitwell J. L., Dickson D. W., et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging: 2008; 29 2 280 289
32. Chang C. C., Chang Y. Y., Chang W. N., et al. Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol: 2009; 16 10 1144 1150
33. Mak E., Zhou J., Tan L. C., Au W. L., Sitoh Y. Y., Kandiah N. Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. J Neurol Neurosurg Psychiatry: 2013
34. Focke N. K., Helms G., Scheewe S., et al. Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp: 2011; 32 11 1905 1915
35. Price S., Paviour D., Scahill R., et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage: 2004; 23 2 663 669
36. Vaillancourt D. E., Spraker M. B., Prodoehl J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology: 2009; 72 16 1378 1384
37. Cochrane C. J., Ebmeier K. P. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology: 2013; 80 9 857 864
38. Nicoletti G., Lodi R., Condino F., et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain: 2006; 129 Pt 10 2679 2687
39. Paviour D. C., Thornton J. S., Lees A. J., Jäger H. R. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord: 2007; 22 1 68 74
40. Baudrexel S., Seifried C., Penndorf B., et al. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Mov Disord: 2014; 29 03 380 387
41. Tsukamoto K., Matsusue E., Kanasaki Y., et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology: 2012; 54 9 947 955
42. Erbetta A., Mandelli M. L., Savoiardo M., et al. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am J Neuroradiol: 2009; 30 8 1482 1487
43. Griffiths P. D., Crossman A. R. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia: 1993; 4 2 61 65
44. Lehéricy S., Sharman M. A., Dos Santos C. L., Paquin R., Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord: 2012; 27 7 822 830
45. Han Y. H., Lee J. H., Kang B. M., et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci: 2013; 325 1-2 29 35
46. Péran P., Cherubini A., Assogna F., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain: 2010; 133 11 3423 3433
47. Lee J. H., Han Y. H., Kang B. M., Mun C. W., Lee S. J., Baik S. K. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy. J Neurol: 2013; 260 8 2094 2101
48. Wang Y., Butros S. R., Shuai X., et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol: 2012; 33 2 266 273
49. Lewis S. J., Shine J. M., Duffy S., Halliday G., Naismith S. L. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord: 2012; 27 10 1262 1267
50. Nie K., Zhang Y., Huang B., et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord: 2013; 19 3 329 334
51. Weiduschat N., Mao X., Beal M. F., Nirenberg M. J., Shungu D. C., Henchcliffe C. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging: 2013
52. Gröger A., Bender B., Wurster I., Chadzynski G. L., Klose U., Berg D. Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. J Neurol Neurosurg Psychiatry: 2013; 84 6 644 649
53. Guevara C. A., Blain C. R., Stahl D., Lythgoe D. J., Leigh P. N., Barker G. J. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol: 2010; 17 9 1193 1202
54. Tedeschi G., Litvan I., Bonavita S., et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain: 1997; 120 Pt 9 1541 1552
55. Watanabe H., Fukatsu H., Katsuno M., et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry: 2004; 75 1 103 109
56. Morgen K., Sammer G., Weber L., et al. Structural brain abnormalities in patients with Parkinson disease: a comparative voxel-based analysis using T1-weighted MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol: 2011; 32 11 2080 2086
57. Tambasco N., Belcastro V., Sarchielli P., et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol: 2011; 18 3 471 477
58. Eckert T., Sailer M., Kaufmann J., et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage: 2004; 21 1 229 235
59. Jokinen P., Helenius H., Rauhala E., Brück A., Eskola O., Rinne J. O. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med: 2009; 50 6 893 899
60. Antonini A., Moresco R. M., Gobbo C., et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci: 2001; 22 1 47 48
61. Oh M., Kim J. S., Kim J. Y., et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med: 2012; 53 3 399 406
62. Burn D. J., Sawle G. V., Brooks D. J. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry: 1994; 57 3 278 284
63. Ghaemi M., Hilker R., Rudolf J., Sobesky J., Heiss W. D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry: 2002; 73 5 517 523
64. Bajaj N., Hauser R. A., Grachev I. D. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry: 2013; 84 11 1288 1295
65. Plotkin M., Amthauer H., Klaffke S., et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm: 2005; 112 5 677 692
66. Antonini A., Leenders K. L., Vontobel P., et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain: 1997; 120 Pt 12 2187 2195
67. Van Laere K., Clerinx K., D'Hondt E., de Groot T., Vandenberghe W. Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med: 2010; 51 4 588 595
68. Vlaar A. M., de Nijs T., Kessels A. G., et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol: 2008; 59 5 258 266
69. Broussolle E., Dentresangle C., Landais P., et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci: 1999; 166 2 141 151
70. Brück A., Aalto S., Rauhala E., Bergman J., Marttila R., Rinne J. O. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord: 2009; 24 7 1009 1015
71. 123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology: 2012; 79 13 1314 1322
72. Zhao P., Zhang B., Gao S. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord: 2012; 18 01 S60 S62
73. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci: 2009; 32 10 548 557
74. Holtbernd F., Eidelberg D. Functional brain networks in movement disorders: recent advances. Curr Opin Neurol: 2012; 25 4 392 401
75. Eckert T., Tang C., Ma Y., et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord: 2008; 23 5 727 733
76. Eidelberg D., Moeller J. R., Dhawan V., et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab: 1994; 14 5 783 801
77. Poston K. L., Tang C. C., Eckert T., et al. Network correlates of disease severity in multiple system atrophy. Neurology: 2012; 78 16 1237 1244
78. Ma Y., Tang C., Spetsieris P. G., Dhawan V., Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab: 2007; 27 3 597 605
79. Tang C. C., Poston K. L., Eckert T., et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol: 2010; 9 2 149 158
80. Jain S., Goldstein D. S. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis: 2012; 46 3 572 580
81. Rascol O., Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord: 2009; 24 02 S732 S741
82. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci: 1998; 155 1 60 67
83. Braune S., Reinhardt M., Schnitzer R., Riedel A., Lücking C. H. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology: 1999; 53 5 1020 1025
84. Courbon F., Brefel-Courbon C., Thalamas C., et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord: 2003; 18 8 890 897
85. Nagayama H., Hamamoto M., Ueda M., Nagashima J., Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry: 2005; 76 2 249 251
86. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F. J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain: 2000; 123 Pt 6 1155 1160
87. Iranzo A., Valldeoriola F., Lomeña F., et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol: 2011; 10 9 797 805
88. Iranzo A., Lomeña F., Stockner H., et al. Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol: 2010; 9 11 1070 1077
89. Holtbernd F., Gagnon J. F., Postuma R. B., et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology: 2014; 82 7 620 627